On November 20, 2024, within the XV Research Conference of the Faculty of Pharmacy of the University of Barcelona and with the collaboration of the UB – Dr. Antoni Esteve i Subirana Chair of Research in Pharmacology, took place the conference on CAR-T cell therapy entitled The academic model of the Hospital Clínic for the treatment with CAR-T cells: results in multiple myeloma presented by Dr. Carlos Fernández De Larrea. Dr. Fernández De Larrea, a renewed hematologist at the Hospital Clínic de Barcelona, presented the efficacy and safety of a new CAR-T cell therapy directed by BCMA, ARI0002H, for patients with relapsed/refractory multiple myeloma (MMRR).
The presentation highlighted the promising results of a phase 1/2 trial, where a 100% response rate was ARI0002H achieved among the 30 patients treated. In particular, 63% of these patients achieved complete remission and 93% experienced a very good partial or better response. In addition, the therapy demonstrated a favorable safety profile, with minimal residual disease negativity in a significant proportion of patients at various follow-up points. Dr. Fernández De Larrea highlighted the therapy’s ability to elicit sustained responses with low-grade toxicity was particularly slowing and offering hope to patients with limited treatment options.
Overall, the conference was a testament to the potential of CAR-T cell therapy to revolutionize the multiple myeloma treatment landscape.
KEYWORDS | Clinical pharmacology, cancer